A Multicenter, Retrospective Analysis of Long-Term Survival in 255 Dogs With Pheochromocytoma Treated With Alpha-Adrenoreceptor Antagonists or Surgery (2010–2021)

IF 2.2 2区农林科学 Q1 VETERINARY SCIENCES

Journal of Veterinary Internal Medicine Pub Date : 2025-09-01 DOI:10.1111/jvim.70220

Matthew M. E. Steele, Marit F. van den Berg, Sara Galac, Ana M. Dordio, Anna Threlfall, Cláudia Gomes, Amanda Paul, Mirja Nolff, Nadja Sieber-Ruckstuhl, Ghita Benchekroun, Fergus Allerton, Beatriz Mendoza, Susanna Spence, Paula Valiente, Alisdair Boag, Federico Fracassi, Alejandra Carranza Valencia, Jorge Pena-Ramos, Ben Lloyd-Bradley, Mayank Seth, Jack Fawsitt, Fang Yu Foo, Romy M. Heilmann, Paolo Silverstrini, Aurélie Lyssens, Emilie Vangrinsven, Clara Casas-Acuna, Alenka Hrovat, Carolina Arenas, Mario Cervone, Carmel T. Mooney, Rodolfo O. Leal, Karolina Maria Piekos, Gerard Olivares, Guillame Ruiz, Sarah J. Caulfield, Sophie Keyte, Anaïs Lamoureux, Christopher J. Scudder, Ruth Gostelow

{"title":"A Multicenter, Retrospective Analysis of Long-Term Survival in 255 Dogs With Pheochromocytoma Treated With Alpha-Adrenoreceptor Antagonists or Surgery (2010–2021)","authors":"Matthew M. E. Steele, Marit F. van den Berg, Sara Galac, Ana M. Dordio, Anna Threlfall, Cláudia Gomes, Amanda Paul, Mirja Nolff, Nadja Sieber-Ruckstuhl, Ghita Benchekroun, Fergus Allerton, Beatriz Mendoza, Susanna Spence, Paula Valiente, Alisdair Boag, Federico Fracassi, Alejandra Carranza Valencia, Jorge Pena-Ramos, Ben Lloyd-Bradley, Mayank Seth, Jack Fawsitt, Fang Yu Foo, Romy M. Heilmann, Paolo Silverstrini, Aurélie Lyssens, Emilie Vangrinsven, Clara Casas-Acuna, Alenka Hrovat, Carolina Arenas, Mario Cervone, Carmel T. Mooney, Rodolfo O. Leal, Karolina Maria Piekos, Gerard Olivares, Guillame Ruiz, Sarah J. Caulfield, Sophie Keyte, Anaïs Lamoureux, Christopher J. Scudder, Ruth Gostelow","doi":"10.1111/jvim.70220","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The survival of dogs with pheochromocytoma (PCC) treated with adrenoreceptor antagonists has not been described or compared to surgically managed cases.</p>\n </section>\n \n <section>\n \n <h3> Hypothesis/Objectives</h3>\n \n <p>The objective of this study is to evaluate the survival of medically and surgically managed dogs with PCC and investigate factors associated with survival.</p>\n </section>\n \n <section>\n \n <h3> Animals</h3>\n \n <p>Two hundred fifty-five dogs with PCC, treated with alpha-adrenoreceptor antagonists (AA) without adrenalectomy (Group 1, <i>n</i> = 75), adrenalectomy +/– AA (Group 2, <i>n</i> = 128), or neither treatment (Group 3, <i>n</i> = 52).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Retrospective, multicenter review of medical records. Median overall survival time (OST) for Groups 1 and 2 combined was calculated using Kaplan–Meier estimates, and then compared between Group 1 and Group 2 using Log-Rank testing. Cox proportional hazard analysis identified factors associated with survival in Groups 1 and 2 individually and combined.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Median OST for all cases was 854 (95% CI: 572–1136) days. Median OST was lower in Group 1 (247 days, 95% CI: 76–418 days) than in Group 2 (927 days, 95% CI: 587–1267 days; <i>p</i> < 0.001). In Group 2, 88/92 dogs (97.8%) that received presurgical AA treatment survived to discharge compared to 23/27 (85.2%) that did not receive AA pretreatment (<i>p</i> = 0.03). Lack of clinical signs at presentation was associated with increased survival in both groups combined (HR 0.5; 95% CI 0.3–0.9; <i>p</i> = 0.02) and in Group 2 alone (HR 0.3; 95% CI 0.1–0.7; <i>p</i> = 0.01).</p>\n </section>\n \n <section>\n \n <h3> Conclusions and Clinical Importance</h3>\n \n <p>Dogs with PCC treated with adrenalectomy have longer survival compared to those managed with AA without adrenalectomy.</p>\n </section>\n </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"39 5","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.70220","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Veterinary Internal Medicine","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvim.70220","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The survival of dogs with pheochromocytoma (PCC) treated with adrenoreceptor antagonists has not been described or compared to surgically managed cases.

Hypothesis/Objectives

The objective of this study is to evaluate the survival of medically and surgically managed dogs with PCC and investigate factors associated with survival.

Animals

Two hundred fifty-five dogs with PCC, treated with alpha-adrenoreceptor antagonists (AA) without adrenalectomy (Group 1, n = 75), adrenalectomy +/– AA (Group 2, n = 128), or neither treatment (Group 3, n = 52).

Methods

Retrospective, multicenter review of medical records. Median overall survival time (OST) for Groups 1 and 2 combined was calculated using Kaplan–Meier estimates, and then compared between Group 1 and Group 2 using Log-Rank testing. Cox proportional hazard analysis identified factors associated with survival in Groups 1 and 2 individually and combined.

Results

Median OST for all cases was 854 (95% CI: 572–1136) days. Median OST was lower in Group 1 (247 days, 95% CI: 76–418 days) than in Group 2 (927 days, 95% CI: 587–1267 days; p < 0.001). In Group 2, 88/92 dogs (97.8%) that received presurgical AA treatment survived to discharge compared to 23/27 (85.2%) that did not receive AA pretreatment (p = 0.03). Lack of clinical signs at presentation was associated with increased survival in both groups combined (HR 0.5; 95% CI 0.3–0.9; p = 0.02) and in Group 2 alone (HR 0.3; 95% CI 0.1–0.7; p = 0.01).

Conclusions and Clinical Importance

Dogs with PCC treated with adrenalectomy have longer survival compared to those managed with AA without adrenalectomy.

Abstract Image

查看原文本刊更多论文

多中心回顾性分析255只嗜铬细胞瘤犬接受α -肾上腺素受体拮抗剂或手术治疗的长期生存率（2010-2021）

背景肾上腺受体拮抗剂治疗嗜铬细胞瘤（PCC）犬的存活率尚未被描述或与手术治疗病例进行比较。假设/目的本研究的目的是评估医学和外科治疗犬PCC的生存率，并探讨与生存率相关的因素。实验动物：255只患PCC的狗，分别接受不切除肾上腺的α -肾上腺受体拮抗剂（AA）治疗（第1组，n = 75）、肾上腺切除+/ - AA治疗（第2组，n = 128）或两者均不治疗（第3组，n = 52）。方法回顾性的、多中心的病历资料。使用Kaplan-Meier估计计算1组和2组的中位总生存时间（OST），然后使用Log-Rank检验比较1组和2组之间的差异。Cox比例风险分析确定了与1组和2组单独或联合生存相关的因素。结果所有病例的中位OST为854天（95% CI: 572-1136）。组1的中位OST（247天，95% CI: 76-418天）低于组2（927天，95% CI: 587-1267天；p < 0.001）。第2组术前AA治疗的88/92只（97.8%）存活至出院，未术前AA治疗的23/27只（85.2%）存活至出院（p = 0.03）。在两组合并（HR 0.5; 95% CI 0.3 - 0.9; p = 0.02）和单独组2 （HR 0.3; 95% CI 0.1-0.7; p = 0.01）中，就诊时缺乏临床体征与生存率增加相关。结论及临床意义与未行肾上腺切除术的犬相比，行肾上腺切除术的犬PCC存活时间更长。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Veterinary Internal Medicine 农林科学-兽医学

CiteScore

4.50

自引率

11.50%

发文量

243

审稿时长

22 weeks

期刊介绍： The mission of the Journal of Veterinary Internal Medicine is to advance veterinary medical knowledge and improve the lives of animals by publication of authoritative scientific articles of animal diseases.